Welcome to our dedicated page for Option Care Health SEC filings (Ticker: OPCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Option Care Health, Inc. filings document the public-company disclosures of a Nasdaq-listed provider of home and alternate-site infusion services. Its common stock is registered under the symbol OPCH, and its regulatory record includes Current Reports on Form 8-K, proxy materials, and exhibits tied to operating results and corporate actions.
OPCH filings cover quarterly and annual financial results, non-GAAP measure reconciliations, Regulation FD investor presentations, amendments to its first lien credit agreement, executive officer changes and related severance matters, and definitive proxy disclosures. The proxy record addresses board governance, stockholder voting matters, executive compensation, and capital allocation context for the company's infusion services business.
Option Care Health, Inc. Chief Operating Officer Luke Whitworth reported two tax-related share dispositions under an equity compensation arrangement. On February 22, 2026, 24,029 shares of common stock were delivered at $35.69 per share to cover taxes, leaving 174,194 shares directly held. On February 20, 2026, 4,015 shares were similarly withheld at $35.69 per share to satisfy tax obligations, after which 198,223 shares were reported as directly owned.
Option Care Health CEO John Charles Rademacher reported a mix of share acquisitions and tax-related dispositions. On February 21, 2026, he exercised 11,087 Restricted Stock Units, each converting into one share of common stock at a stated price of $0.0000 per share.
To cover tax obligations, he reported multiple F-code tax-withholding dispositions of common stock on February 20–22, 2026 at $35.69 per share. After these transactions, his direct ownership stood at 693,702 shares of common stock.
Option Care Health, Inc. reported insider transactions by its General Counsel and Corporate Secretary, Collin Smyser. On February 22, 2026, Smyser disposed of 15,433 shares of common stock at $35.69 per share, and on February 20, 2026, disposed of another 2,012 shares at the same price. Both transactions were coded “F,” meaning shares were surrendered to satisfy tax obligations rather than sold in open-market trades. After these transactions, Smyser held 76,770 shares directly, plus an additional 2,500 shares held indirectly through a revocable trust.
Option Care Health, Inc. is the largest independent U.S. provider of home and alternate-site infusion services, operating 196 locations in 43 states and a team of more than 5,000 clinicians. It runs 87 full-service pharmacies and 109 stand‑alone ambulatory infusion suites to treat complex and chronic conditions ranging from infections to neurological and inflammatory disorders.
The business is highly dependent on third‑party payers; for 2025, 88% of revenue came from managed care and other nongovernmental payers and 12% from direct government programs like Medicare and Medicaid. Its largest payer contributed 14% of revenue, and about 68% of drug and supply purchases came from four vendors, creating concentration risk.
The company discloses $1,176.3 million of debt as of December 31, 2025, split between a $676.3 million first‑lien term loan and $500.0 million of 4.375% senior notes due 2029. It notes federal reimbursement pressure, including Medicare sequestration and a CMS‑negotiated 66% price cut effective January 2026 for one portfolio therapy under the Inflation Reduction Act, as potential headwinds. As of June 30, 2025, non‑affiliate equity value was about $5.27 billion, with 156,447,972 common shares outstanding as of February 19, 2026, and a share repurchase authorization increased to $1 billion in January 2026.
Option Care Health reported solid fourth quarter and full-year 2025 results with continued growth and significant shareholder returns. Fourth quarter net revenue reached $1,465.4 million, up 8.8%, while net income was $58.5 million, down 2.7%. GAAP diluted EPS rose 5.7% to $0.37, and Adjusted EBITDA increased 3.7% to $126.0 million. The company repurchased $95 million of stock in the quarter.
For full year 2025, net revenue grew 13.0% to $5,649.5 million, with net income of $207.6 million, down 2.0%. GAAP diluted EPS increased 3.3% to $1.27, and Adjusted EBITDA rose 6.2% to $471.3 million. Adjusted diluted EPS was $1.72, up 8.9%, and operating cash flow was $258.4 million. The company repurchased $307 million of stock during the year.
Looking to 2026, Option Care Health expects net revenue of $5.8 billion to $6.0 billion, Adjusted EBITDA of $480 million to $505 million, Adjusted diluted EPS of $1.82 to $1.92, and operating cash flow of at least $340 million, signaling confidence in continued growth.
Option Care Health Chief Operating Officer Luke Whitworth reported two equity-related transactions in company common stock. He received a grant of 30,423 restricted stock units at no cost, which vest in three equal annual installments. Separately, 508 shares were disposed of to cover tax withholding obligations tied to equity compensation.
Option Care Health, Inc. Chief Growth Officer Christopher L. Grashoff reported mixed equity transactions. He received a grant of 12,678 shares of common stock at no cost as part of a restricted stock unit award. According to the footnote, one third of these units vest on each of the first three anniversaries of the grant date. Separately, 259 shares were disposed of at $35.24 per share to cover tax obligations associated with equity compensation, leaving him with 35,880 directly held shares after that tax-withholding transaction and 48,558 shares after the award grant.
Option Care Health, Inc. Chief Human Resources Officer Michael Bavaro reported two equity transactions. He acquired 9,579 shares of common stock as a restricted stock unit award at a stated price of $0.00 per share. These units vest in three equal annual installments beginning on the first anniversary of the grant date.
He also disposed of 551 shares of common stock at $35.24 per share in a tax-withholding transaction used to satisfy obligations associated with equity compensation. After these transactions, his directly held common stock balance reported in the filing increased compared with prior holdings.
Option Care Health Chief Accounting Officer reports equity grant and tax share withholding. Nicole Maggio received 4,226 shares of common stock on February 18, 2026 as a grant or award at a stated price of $0 per share, bringing her direct holdings to 30,455 shares after that grant.
On February 17, 2026, 247 shares of common stock were disposed of at $35.24 per share to satisfy tax withholding obligations, leaving 26,229 directly owned shares after that tax-related transaction. The footnote explains that the restricted stock units from this award vest in three equal installments on each of the first, second, and third anniversaries of the grant date.
Option Care Health, Inc. reported that Chief Executive Officer John Charles Rademacher acquired 78,876 shares of common stock through a grant of restricted stock units. The award was at a stated price of $0.00 per share and increases his directly held position to 831,057 shares. These restricted stock units vest in three equal annual installments on the first, second, and third anniversaries of the grant date.